Comparison of Two Different Preparations of HIV Immune Globulin for Efficiency of Neutralization of HIV Type 1 Primary Isolates
- 1 January 2002
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 18 (1), 49-56
- https://doi.org/10.1089/088922202753394718
Abstract
The objective of this study was to compare the virus-neutralizing ability of two different preparations of HIV immune globulin (HIVIG) isolated from human plasma units that were selected according to two different criteria. The first preparation, designated NYBC-HIVIG, was isolated from plasmas with high neutralizing antibody titers against HIV-1. The second preparation, designated NABI-HIVIG, was isolated from plasma with high titers of antibody to the HIV-1 p24 antigen. A panel of primary HIV-1 isolates was phenotypically characterized by their ability to induce syncytia in CEM-SS cells. Neutralization of this panel of primary isolates by the two HIVIG preparations was assessed in HeLa-MAGI-CCR5 cells, utilizing a luminescence-based assay. In addition, the reactivities of these two preparations with a panel of HIV-1 gp120 proteins, V3 loop peptides, and HIV-1 p24 antigen were determined. Both HIVIG preparations were shown to neutralize all virus isolates tested. However, doses of NABI-HIVIG required for 50% virus neutralization were 2.2- to 4.4- fold (mean, 3.2-fold) higher than the required doses of NYBC-HIVIG. Comparative antigen-binding assays showed that, although NABI-HIVIG possessed higher titers of antibody to HIV-1 p24, NYBC-HIVIG generally contained higher titers of antibody to HIV-1 gp120 and V3 peptides. These experiments show that the criteria used for selection of source plasmas for isolation of HIVIG can influence the effective concentration of virus-neutralizing antibody present in the final immunoglobulin preparation, and may determine the doses required for clinical efficacy.Keywords
This publication has 29 references indexed in Scilit:
- Use of Human Immunodeficiency Virus (HIV) Human Hyperimmune Immunoglobulin in HIV Type 1–Infected Children (Pediatric AIDS Clinical Trials Group Protocol 273)The Journal of Infectious Diseases, 2000
- Safety and Pharmacokinetics of Hyperimmune Anti-Human Immunodeficiency Virus (HIV) Immunoglobulin Administered to HIV-Infected Pregnant Women and Their NewbornsThe Journal of Infectious Diseases, 1997
- Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.JCI Insight, 1994
- Nonaffinity Purification of Recombinant gp120 for Use in AIDS Vaccine DevelopmentAIDS Research and Human Retroviruses, 1993
- Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.JCI Insight, 1993
- Prevention of HIV Infection by Passive Immunization with HIV ImmunoglobulinAIDS Research and Human Retroviruses, 1991
- Use of Cytomegalovirus Immune Globulin to Prevent Cytomegalovirus Disease in Renal-Transplant RecipientsNew England Journal of Medicine, 1987
- Simple, Rapid, Quantitative, Syncytium-Forming Microassay for the Detection of Human Immunodeficiency Virus Neutralizing AntibodyAIDS Research and Human Retroviruses, 1987
- Nucleotide Sequence and Expression of an AIDS-Associated Retrovirus (ARV-2)Science, 1985
- Prophylaxis of varicella in high-risk children: Dose-response effect of zoster immune globulinThe Journal of Pediatrics, 1981